XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 10, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events
March 08, 2022 07:30 ET
|
XOMA Corporation
Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer Received $1.2 million from three milestone payments, two of which were from a single...
XOMA to Present at the 42nd Annual Cowen Health Care Conference
March 01, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA to Present at Aegis Capital Corp Investor Conference
February 17, 2022 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Declares Quarterly Preferred Stock Dividends
December 23, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at Upcoming Investor Conferences
December 21, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of...
XOMA Announces Evolution of Company Leadership and Succession Planning
December 16, 2021 07:30 ET
|
XOMA Corporation
Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company is launching Chief Executive Officer search; Jim...
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
November 04, 2021 07:40 ET
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3...
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events
November 04, 2021 07:30 ET
|
XOMA Corporation
Added eight assets to its portfolio of potential milestone and royalty assets in 2021 NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the treatment of...
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)’s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...